Welcome to our dedicated page for Nu Skin Enter SEC filings (Ticker: NUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nu Skin Enterprises, Inc. (NYSE: NUS) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its integrated beauty and wellness operations. These SEC filings cover the performance of the Nu Skin and Rhyz businesses, including revenue, margins, segment results and key metrics such as Customers, Paid Affiliates and Sales Leaders in the core Nu Skin business.
Among the most important filings for NUS are its annual reports on Form 10-K, which describe the company’s business model, risk factors, segment structure, accounting policies and long-term trends, and its quarterly reports on Form 10-Q, which update investors on interim financial performance and regional results. Nu Skin also uses Form 8-K to report material events, such as the release of quarterly and year-to-date financial results, including revenue, earnings per share, non-GAAP measures like constant-currency revenue change and adjusted EPS, and commentary on operating conditions.
In addition, investors can review proxy statements for information on governance and executive compensation, and Form 4 filings to track insider transactions by directors and officers. These documents help clarify how Nu Skin’s leadership and affiliate-driven model align with shareholder interests.
On this page, Stock Titan provides real-time access to Nu Skin’s latest SEC filings as they are posted to EDGAR, along with AI-powered summaries that explain the key points in clear language. Instead of reading entire multi-hundred-page 10-Ks or detailed 10-Qs, you can use these summaries to understand segment performance, changes in margins, updates on initiatives such as Prysm iO and regional expansion, and other material disclosures. Filings related to non-GAAP measures, restructuring and gains or losses from business sales are also highlighted so you can see how they affect reported results.
Nu Skin Enterprises (NUS) insider transaction: Chief Product Officer Steven Hatchett reported buying 5,500 shares of Class A Common Stock on 11/11/2025 at $9.61 per share, according to a Form 4 filing.
Following the purchase, Hatchett beneficially owns 167,565 shares, held directly. The filing was signed by attorney-in-fact Gregory Belliston on 11/12/2025.
Nu Skin Enterprises (NUS) reported Q3 2025 results. Revenue was $364.2 million, down 15% year over year as macro headwinds weighed on demand and field activity. Operating income rose to $21.6 million from $18.2 million. Net income was $17.1 million ($0.34 diluted EPS) versus $8.3 million a year ago.
For the first nine months of 2025, revenue was $1,114.8 million, down 13% year over year. Net income reached $145.7 million, reflecting a $176.2 million gain on the January sale of the Mavely business. Core costs were lower: selling and G&A declined versus last year, and restructuring charges were significantly lower than 2024.
The balance sheet strengthened. Cash and cash equivalents were $251.8 million versus $186.9 million at year-end 2024. Long-term debt fell to $209.0 million from $363.6 million, aided by $220.0 million of debt payments year-to-date, including a $115.0 million term-loan paydown funded by sale proceeds. The company paid quarterly dividends of $0.06 per share and repurchased $10.0 million of stock year to date, with $152.4 million remaining under the authorization. As of November 1, 2025, 48,750,076 Class A shares were outstanding.
Nu Skin Enterprises (NUS) furnished an 8‑K announcing it issued a press release with financial results for the three‑ and nine‑month periods ended September 30, 2025. The release is included as Exhibit 99.1 and the information under Item 2.02 is furnished, not filed, under the Exchange Act. The report lists Class A Common Stock trading on the NYSE and is signed by CFO James D. Thomas.
Edwina D. Woodbury, a director of Nu Skin Enterprises, Inc. (NUS), reported an acquisition of Class A common stock on 09/10/2025. The filing shows shares were acquired at a price of $11.52 under the company’s Deferred Compensation Plan via dividend reinvestment. Following the transaction, Ms. Woodbury beneficially owns 42,969 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025. The filing lists the transaction as a direct ownership change and notes the dividend reinvestment as the reason for the share increase.
Laura Nathanson, a director of Nu Skin Enterprises (NUS), reported a sale of 6,489 shares of Class A common stock on 09/04/2025 at a price of $12.22 per share. After the transaction she beneficially owns 33,149 shares, reported as directly held. The Form 4 was signed by an attorney-in-fact on her behalf.
Nu Skin Enterprises insider sale summary. EVP and General Counsel Chayce Clark reported a sale of 20,000 shares of Class A common stock on 09/03/2025 at a weighted-average price of $11.97 per share. After the reported disposition, the reporting person beneficially owned 233,140 shares, held directly. The Form 4 shows no derivative transactions and was signed by an attorney-in-fact on behalf of the reporting person on 09/04/2025. The filing includes an explanation that the reported price is a weighted average from multiple trades between $11.96 and $12.01.
NuSkin Enterprises, Inc. (NUS) Form 144 shows a proposed sale of 6,489 Class A shares through William Blair in Chicago, to be executed approximately on 09/04/2025 on the NYSE. The filing lists an aggregate market value of $77,868.00 and reports 49,497,715 Class A shares outstanding for the issuer.
The 6,489 shares were acquired from the issuer as compensation across annual grant dates: 04/30/2021 (422 shares), 04/30/2022 (2,467), 04/30/2023 (3,179) and 04/30/2024 (421), with matching payment dates. The filer reports no securities sold in the past three months and includes the standard attestation regarding absence of undisclosed material adverse information.
Nu Skin Enterprises (NUS) filing a Form 144 notifies the SEC of a proposed sale of 20,000 Class A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $239,433.56 and approximately 49,497,715 Class A shares outstanding. The securities listed were acquired as restricted stock vesting from the issuer on multiple dates between 02/15/2022 and 02/15/2024, with individual lot sizes shown. The filer reports no securities sold in the past three months and affirms they possess no undisclosed material adverse information about the issuer. The notice includes required signature and legal attestation language.
Daniel W. Campbell, a director of Nu Skin Enterprises (NUS), reported open-market sales of Class A common stock on 08/29/2025. The filing shows two disposal transactions: 9,046 shares sold at a weighted-average price of $12.12 and 23,391 shares sold at a weighted-average price of $12.10, for total reported disposals of 32,437 shares. After the transactions the report shows 39,216 shares held directly and 53,375 shares held indirectly, including shares held by an irrevocable family trust and by a limited liability company controlled by the reporting person and his spouse.
Form 144 filed for NuSkin Enterprises, Inc. (NUS) reports a proposed sale of 23,391 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $283,117.65. The filing lists the approximate date of sale as 08/29/2025 and shows 49,497,715 shares outstanding. All 23,391 shares were acquired as gifts from affiliate Daniel Campbell on 11/02/2021, with donor acquisition dates and per-lot amounts totaling the 23,391 shares. The filer reports "Nothing to Report" for securities sold in the past three months and includes the standard representation that no undisclosed material adverse information about the issuer is known.
FAQ
What is the current stock price of Nu Skin Enter (NUS)?
What is the market cap of Nu Skin Enter (NUS)?
